AKT1 and autosomal dominant cerebellar ataxia: We have recently demonstrated that a biological fusion protein inhibitor (TAT-ΔPTENp85) and a small chemical inhibitor (VO-OHpic) of phosphatase PTEN, that both negatively regulates Akt activity, improved survival from ischemic/reperfusion injury in a mouse cardiomyocyte I/R model and a mouse SCA model, respectively [17, 18].